ArticleBMC neurology2026
Two mild phenotype molybdenum cofactor deficiency patients with novel MOCS2 mutation and immunological treatment after COVID-19 infection.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMolybdenum cofactor deficiency type B (MoCD-B) is a rare autosomal recessive metabolic disorder caused by mutations in MOCS2. Patients with mild phenotypes may experience infection-related neurological deterioration followed by partial spontaneous recovery. This study presents the first reported cases of acute encephalopathy triggered by SARS-CoV-2 infection in patients with mild MoCD-B and provides clinical insights into the course of neurological symptoms and corresponding interventions.
methodsClinical and genetic information were collected from two patients showing acute encephalopathy, each harboring mutated molybdenum cofactor synthesis gene 2 (MOCS2).
resultsBoth patients developed acute encephalopathy following SARS-CoV-2 infection. Clinical manifestations included motor regression, dystonia, and brain MRI abnormalities predominantly involving the bilateral globus pallidus and cerebral peduncles. Biochemical testing revealed persistently low serum uric acid and hypohomocysteinemia. Immunological analysis showed positive thyroid autoantibodies. Cerebrospinal fluid (CSF) analysis indicated elevated levels of interleukin-8 and other pro-inflammatory cytokines during the acute phase. Whole-exome sequencing identified a known pathogenic variant (c.16 C > T, p.Gln6Ter) and a novel missense variant (c.257G > T, p.Ser86Ile) in MOCS2. Both patients received immunotherapy with intravenous immunoglobulin (IVIG) and methylprednisolone, resulting in gradual symptom improvement.
conclusionThis study expands the genetic spectrum of MoCD-B by identifying for the first time a novel MOCS2 variant (c.257G > T, p.Ser86Ile). In infants, acute neurological deterioration after infection accompanied by persistent hypouricemia and bilateral globus pallidus lesions should prompt consideration of mild MoCD-B. Our observations do not provide sufficient evidence to support routine immunotherapy for MoCD-B patients after SARS-CoV-2 infection; treatment management should be guided by established recommendations for COVID-19–associated neurological complications. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.